microRNA-625 inhibits tumorigenicity by suppressing proliferation, migration and invasion in malignant melanoma.
microRNA-625 inhibits tumorigenicity by suppressing proliferation, migration and invasion in malignant melanoma.
复制标题
microRNA-625通过抑制恶性黑色素瘤的增殖、迁移和侵袭来抑制致瘤性
DOI：
10.18632/oncotarget.14710
复制
发表时间：
2017-02-21
期刊：
影响因子：
--
通讯作者：
Gu J
中科院分区：
文献类型：
--
作者：
Fang W;Fan Y;Fa Z;Xu J;Yu H;Li P;Gu J
在几种癌症中观察到 microRNA (miR)-625 表达失调。尽管miR-625在人类恶性黑色素瘤中的临床意义和功能尚不清楚，但微小RNA是恶性黑色素瘤发生和进展的重要因素。因此，使用 qPCR 测定了 36 对恶性黑色素瘤和邻近非肿瘤组织中的 miR-625 表达水平。使用 CCK-8、transwell 实验和裸鼠皮下肿瘤模型研究了 miR-625 失调对恶性黑色素瘤细胞增殖、伤口愈合、体外迁移和侵袭以及体内致瘤性的影响。利用生物信息学分析和荧光素酶报告系统预测并确认miR-625的靶基因。恶性黑色素瘤中 miR-625 水平经常降低。 miR-625 的异位表达抑制恶性黑色素瘤的增殖、伤口愈合、迁移和致瘤性。此外，miR-625 至少部分通过抑制潜在靶标 SOX2 发挥作用。这些结果表明miR-625是一种肿瘤抑制因子，可抑制恶性黑色素瘤的发生和进展，这表明miR-625有可能成为恶性黑色素瘤的新诊断标志物和治疗靶点。
Dysregulated microRNA (miR)-625 expression has been observed in several kinds of cancer. MicroRNAs are important factors in the development and progression of malignant melanoma, though the clinical significance and function of miR-625 in human malignant melanoma remain unclear. Levels of miR-625 expression were therefore determined in 36 pairs of malignant melanoma and adjacent non-tumor tissue using qPCR. The effects of miR-625 dysregulation on malignant melanoma cell proliferation, wound healing, migration and invasion in vitro and tumorigenicity in vivo were investigated using CCK-8, transwell assays, and a nude mouse subcutaneous tumor model. Bioinformatics analysis and luciferase reporter system were used to predict and confirm the target gene of miR-625. miR-625 levels were frequently decreased in malignant melanoma. Ectopic expression of miR-625 suppressed proliferation, wound healing, migration, and tumorgenicity in malignant melanoma. Moreover, miR-625 acted, at least in part, by suppressing potential target SOX2. These results show that miR-625 is a tumor suppressor that inhibits the development and progression of malignant melanoma, which suggests miR-625 is potentially a new diagnostic marker and therapeutic target of malignant melanoma.